Naomi Haas, MD, from the Hospital at the University of Pennsylvania, explains that most trials regarding neoadjuvant therapy ...

In this segment on advanced renal cell carcinoma, Dr. Wulff focuses on the role of cabozantinib across different treatment settings and how clinicians decide between monotherapy and combination ...

Immunotherapy and targeted therapy are often the first lines of treatment for advanced kidney cancer, with surgery and radiation also possible.

Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI ...

Metastatic kidney survival rates don’t predict individual outcomes. A number of factors, including overall health, tumor characteristics, and response to treatment, influence prognosis and survival.

The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company pioneering molecular glue ...

The advanced renal cell carcinoma (RCC) treatment market has demonstrated significant growth, with projections indicating an ...

Many people with cancer can benefit from a second medical opinion. Those with advanced renal cell carcinoma (RCC), who are likely considering multiple treatment options, if not combinations of ...

Combining CEUS with pre-ablation MR or CT images improved clinicians’ ability to delineate tumor borders and detect RCC recurrence after percutaneous ablation. CEUS images were successfully fused with ...

OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...

Learn diagnosis, treatments, side effects and key questions to help guide shared decisions with your oncology team after stage 4 ccRCC diagnosis. Stage 4 clear cell renal cell carcinoma (ccRCC) is the ...

Locally advanced ccRCC at stage III typically reflects T3 invasion into renal vein/IVC or perinephric fat, with optional N1 regional lymph node involvement, without distant metastases. Definitive risk ...